This WNK463-mediated anticancer effect of activated PBMCs was partially reversed by PD-L1 overexpression in cancer cells (Supplementary Fig. 2e, f), suggesting that PD-L1 depletion in cancer cells at least partially contributes to enhanced anticancer immunity. The gene discussed is CD274; the disease is cancer.